CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Background Glioblastoma (GBM) is a devastating primary brain tumor with a highly immunosuppressive tumor microenvironment, and treatment with oncolytic viruses (OVs) has emerged as a promising strategy for these tumors. Our group constructed a new OV named Delta-24-ACT, which was based on the Delta-...
Saved in:
| Main Authors: | Hong Jiang, Sandra Hervás-Stubbs, Sara Labiano, Candelaria Gomez-Manzano, Juan Fueyo, Marta Alonso, Zhihong Chen, Montserrat Puigdelloses, Marc Garcia-Moure, Virginia Laspidea, Marisol Gonzalez-Huarriz, Marta Zalacain, Lucia Marrodan, Naiara Martinez-Velez, Daniel De la Nava, Iker Ausejo, Guillermo Herrador, Dolores Hambardzumyan, Ana Patino Garcia, Jaime Gállego Pérez-Larraya |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/7/e002644.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
by: Dipongkor Saha, et al.
Published: (2020-05-01) -
Improving immunovirotherapies: the intersection of mathematical modelling and experiments
by: Christine E. Engeland, et al.
Published: (2022-06-01) -
Cracking the code for more effective treatments for hepatocellular carcinomas: Promise and a path for immunovirotherapy
by: Emil Lou
Published: (2025-03-01) -
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
by: Arantza Azpilikueta, et al.
Published: (2022-03-01) -
Gluteoplasty with fat grafting: experience in 137 patients
by: Fabiel Spani Vendramin, et al.
Published: (2022-06-01)